Alberto Toso

Alberto Toso joined Alentis as Head of Oncology in October 2021, bringing more than six years of industrial drug development experience in Immune Oncology (IO) and Targeted therapy. He was most recently the Department Head in the molecular targeted therapy group, Oncology at Roche, Basel, Switzerland. In this role, he was responsible for leading different small molecule projects for IO at varying stages of development. Alberto brings expertise in developing new drugs as well as a rationalized approach for combination strategies related to small and large molecules in Oncology.

During his five years as a post doc at the Institute of Oncology Research in Bellinzona, Switzerland, he developed and characterized mouse models for prostate cancer. His work in oncology has been published in top scientific Journals such as Nature, Nature Communications and Cell Reports.

Alberto holds a PhD in Biochemistry from ETH in Zurich, Switzerland.